Coeptis Therapeutics (COEP) Short Interest Ratio & Short Volume

Short interest is the volume of Coeptis Therapeutics shares that have been sold short but have not yet been closed out or covered. As of May 15th, traders have sold 76,600 shares of COEP short. 0.28% of Coeptis Therapeutics' shares are currently sold short. Learn More on Coeptis Therapeutics' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.28% of Coeptis Therapeutics' floating shares are currently sold short.

Coeptis Therapeutics saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 76,600 shares, a decline of 49.1% from the previous total of 150,500 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Coeptis Therapeutics currently has issued a total of 37,119,000 shares. Some of Coeptis Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Coeptis Therapeutics currently has a public float of 27,350,000 shares.

0.28% of Coeptis Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to Coeptis Therapeutics: OKYO Pharma Limited (0.34%), Brainstorm Cell Therapeutics Inc. (2.01%), Achilles Therapeutics plc (0.04%), Quince Therapeutics, Inc. (6.17%), Estrella Immunopharma, Inc. (0.10%), Surrozen, Inc. (1.66%), MiNK Therapeutics, Inc. (5.18%), Pluri Inc. (0.77%), SAB Biotherapeutics, Inc. (0.30%), Evaxion Biotech A/S (0.89%),

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks.

Short selling COEP is an investing strategy that aims to generate trading profit from Coeptis Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Coeptis Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of COEP, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including COEP, twice per month. The most recent reporting period available is May, 15 2024.